Nasdaq dbtx.

To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...DBX NASDAQ. DBX NASDAQ. DBX NASDAQ. DBX NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview . News Ideas Financials Technicals Forecast . DBX chart. Today 0.93% 5 days −1.40% 1 month −4.98% 6 months 20.14% Year to date 15.52% 1 year 21.65% 5 years 4.77% All time −9.90%. Key stats.BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Nasdaq Listed 1 High Technical Attribute Add to Watchlist Add to Portfolio DBTX DBTX FINANCIALS DBTX Financials Income Statement Balance Sheet Cash …

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Feb 9, 2022 · BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... Top Five Stock Market Gainers: TNGX, DBTX, MRTX, CTG, OPRT

Company profile page for Decibel Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information 10-Nov-2023 ... ... NASDAQ：DBTX），一家致力于发现和开发恢复和改善听力和平衡的变革性治疗方法的临床生物技术公司，并附带一项额外的不可交易或有价值权（CVR），在 ...Decibel Therapeutics ( NASDAQ: DBTX) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 ...See the latest Decibel Therapeutics Inc Ordinary Shares stock price (NASDAQ:DBTX), related news, valuation, dividends and more to help you make your …

The European Commission (EC) granted orphan drug designation to Decibel Therapeutics' (NASDAQ:DBTX) gene therapy DB-OTO to treat profound, congenital hearing loss caused by mutations of the ...

Decibel Therapeutics ( NASDAQ: DBTX) is an early-stage gene therapy company focused on developing new medicines for hearing and balance disorders. The company’s biological hypothesis is centered ...

Jan 24, 2023 · Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ... NASDAQ:DBTX Decibel Therapeutics (DBTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively …Every investor in Decibel Therapeutics, Inc. (NASDAQ:DBTX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see ...DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders.Decibel Therapeutics ( NASDAQ: DBTX) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 ...

Mar 30, 2023 · BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... Jun 28, 2022 · BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ... Find the latest historical data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. Decibel Therapeutics, Inc. Common Stock (DBTX) Historical Data | Nasdaq Skip to main...BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...USA, PLSE, NASDAQ. 080134288, Synergy Chc Corp. USA, SNYR, OTHER OTC Market. 080143728, Decibel Therapeutics, Inc. USA, DBTX, NASDAQ. 080144027, Ulta Beauty, ...1,992.00 -0.80(-0.04%) Decibel Therapeutics, Inc. (DBTX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.9100 0.0000 (0.00%) At close: 03:00PM EST 1d 5d 1m 6m YTD 1y 5y...

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

https://www.decibeltx.com. Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company’s product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to ...Shareholders will receive $4.0000 and 1 share of DBTX^ for each share of DBTX previously held. ... NASDAQ. Copy link to clipboard. June 1, 2021. June 1, 2021.BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and... DBTX : 4.33 …Decibel Therapeutics Inc (DBTX). Sector: HEALTH CARE. Industry: BIOTECHNOLOGY ... Fidelity Nasdaq Composite Index Fund, Long, EC, 9,952, $50,357, 0.00, 0.00 ...Motley Fool Issues Rare Triple-Buy Alert. This Stock Could Be Like Buying Amazon for $3.19. Find real-time Symbol not found stock quotes, company profile, news and forecasts from CNN Business.BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Dec 3, 2023 · Decibel Therapeutics (NASDAQ:DBTX) has a recorded net income of -$63.01 million. DBTX has generated -$2.53 earnings per share over the last four quarters. What is Decibel Therapeutics's EPS forecast for next year?

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

The European Commission (EC) granted orphan drug designation to Decibel Therapeutics' (NASDAQ:DBTX) gene therapy DB-OTO to treat profound, congenital hearing loss caused by mutations of the ...When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Every investor in Decibel Therapeutics, Inc. (NASDAQ:DBTX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see ... BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary.Motley Fool Issues Rare Triple-Buy Alert. This Stock Could Be Like Buying Amazon for $3.19. Find real-time Symbol not found stock quotes, company profile, news and forecasts from CNN Business.Baird Downgrades Decibel Therapeutics (DBTX) msn.com - August 10 at 1:37 PM: Decibel Therapeutics, Inc. (NASDAQ:DBTX) surges 80%; private equity firms who own 41% shares profited along with institutions finance.yahoo.com - August 10 at 7:43 AM: Complaints about airplane noise rise at Reagan National, Dulles washingtonpost.com - August 9 at 9:34 PM The average one-year price target for Decibel Therapeutics (NASDAQ:DBTX) has been revised to 14.69 / share. This is an increase of 9.37% from the prior estimate of 13.43 dated June 1, 2023. 09-Aug-2023 ... Decibel Therapeutics (NASDAQ:DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ:REGN).Feb 12, 2021 · Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ...

DermTech Inc (NASDAQ:DMTK) said its fourth-quarter revenues increased 33% year-over-year to $2.1 million. The net loss per share widened from 48 cents to 43 cents. The net loss per share widened ...Aug 30, 2022 · Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a ... Company profile page for Decibel Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact informationInstagram:https://instagram. syss stockbest trading cards to collect for profitnsptv8 coupe BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... spy next dividend date 2023bp price stock BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and... DBTX : 4.33 … trade options roth ira (DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...